By defining distinct migration factors and surface markers of LTB+/CD161+ T09 cells, a CNS-homing population that colonizes the CNS of progressive MS patients, we lay the groundwork for a therapeutic opportunity to target this pathomechanism. This evidence concerns the gene LTB and myeloid sarcoma.